Regeneron Pharmaceuticals, Inc.
Joseph J Larosa (EVP General Counsel and Secret) sells REGN shares
AI-generated summary
Joseph J Larosa, EVP General Counsel and Secret of Regeneron Pharmaceuticals, Inc., exercised options for 12,283 shares valued at $4,691,123.36, had 8,686 shares withheld for taxes valued at $8,256,043, and sold 4,466 shares in open-market sales for $4,311,889.96. Following these transactions, the insider directly held 38,906 shares of Common Stock.
Key facts
- Insider
- Joseph J Larosa · EVP General Counsel and Secret
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | M · exercise or conversion of a derivative | +12,283 | $381.92 | $4,691,123.36 | 52,058 | Direct |
| Nov 2, 2026 | F · tax withholding | −8,686 | $950.50 | $8,256,043.00 | 43,372 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F1 | −3,939 | $965.41 | $3,802,749.99 | 39,433 | Direct |
| Nov 2, 2026 | S · open-market saleFootnotes F2 | −527 | $966.11 | $509,139.97 | 38,906 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F3 | −12,283 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F2 Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
- F3 The stock option award vested in four equal annual installments, commencing one year after the date of grant.
More REGN filings
- 144
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 3, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.